Regeneron Pharmaceuticals: Hyperlipoproteinemia Type II trials
The registry lists 10 Hyperlipoproteinemia Type II studies with Regeneron Pharmaceuticals as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 2 3Phase 3 6Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial HypercholesterolemiaCompletedNCT04233918Phase 3Results posted
- Long Term Safety Study of PRALUENTTerminatedNCT03694197Phase 4Results posted
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03409744Phase 3Results posted
- Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03399786Phase 3Results posted
- Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03156621Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompletedNCT02326220Phase 3Results posted
- Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02265952Phase 2Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
- A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
- Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted